These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 2459540)
21. Overview of the clinical development of quinapril. Frank GJ Clin Cardiol; 1990 Jun; 13(6 Suppl 7):VII13-8. PubMed ID: 2189616 [TBL] [Abstract][Full Text] [Related]
22. Antihypertensive effects and arterial haemodynamic alterations during angiotensin converting enzyme inhibition. London GM; Pannier B; Vicaut E; Guérin AP; Marchais SJ; Safar ME; Cuche JL J Hypertens; 1996 Sep; 14(9):1139-46. PubMed ID: 8986916 [TBL] [Abstract][Full Text] [Related]
23. Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders. Culy CR; Jarvis B Drugs; 2002; 62(2):339-85. PubMed ID: 11817979 [TBL] [Abstract][Full Text] [Related]
24. The safety and efficacy of quinapril in the treatment of mild to moderate essential hypertension. Frishman WH Clin Cardiol; 1990 Jun; 13(6 Suppl 7):VII19-25. PubMed ID: 2189617 [TBL] [Abstract][Full Text] [Related]
25. Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders. Plosker GL; Sorkin EM Drugs; 1994 Aug; 48(2):227-52. PubMed ID: 7527326 [TBL] [Abstract][Full Text] [Related]
26. Enalapril and quinapril improve endothelial vasodilator function and aortic eNOS gene expression in L-NAME-treated rats. De Gennaro Colonna V; Rossoni G; Rigamonti A; Bonomo S; Manfredi B; Berti F; Muller E Eur J Pharmacol; 2002 Aug; 450(1):61-6. PubMed ID: 12176110 [TBL] [Abstract][Full Text] [Related]
27. Quinapril versus atenolol in the treatment of mild to moderate essential hypertension. Bahena JH; Estrella ME; Muñoz M Clin Ther; 1992; 14(4):527-36. PubMed ID: 1525787 [TBL] [Abstract][Full Text] [Related]
28. Circadian activity of the endogenous fibrinolytic system in stable coronary artery disease: effects of beta-adrenoreceptor blockers and angiotensin-converting enzyme inhibitors. Sayer JW; Gutteridge C; Syndercombe-Court D; Wilkinson P; Timmis AD J Am Coll Cardiol; 1998 Dec; 32(7):1962-8. PubMed ID: 9857879 [TBL] [Abstract][Full Text] [Related]
29. Quinapril hydrochloride effects on renal function in patients with renal dysfunction and hypertension: a drug-withdrawal study. Miller MA; Texter M; Gmerek A; Robbins J; Shurzinske L; Canter D Cardiovasc Drugs Ther; 1994 Apr; 8(2):271-5. PubMed ID: 7918140 [TBL] [Abstract][Full Text] [Related]
30. Pilot study of the effects of the angiotensin-converting enzyme inhibitor CI-906 on patients with essential hypertension. Gavras I; Vlahakos D; Melby JC; Gavras H J Clin Pharmacol; 1984; 24(8-9):343-50. PubMed ID: 6090509 [TBL] [Abstract][Full Text] [Related]
31. Differing effects of two angiotensin converting enzyme inhibitors, captopril and CI-906, on diuresis and the urinary excretion of kallikrein and prostaglandins in spontaneously hypertensive rats. Säynävälammi P; Pörsti I; Nurmi AK; Seppälä E; Laitinen LA; Manninen V; Ylitalo P; Vapaatalo H Scand J Urol Nephrol Suppl; 1984; 79():23-7. PubMed ID: 6089314 [TBL] [Abstract][Full Text] [Related]
32. The rapidity of drug dose escalation influences blood pressure response and adverse effects burden in patients with hypertension: the Quinapril Titration Interval Management Evaluation (ATIME) Study. ATIME Research Group. Flack JM; Yunis C; Preisser J; Holmes CB; Mensah G; McLean B; Saunders E Arch Intern Med; 2000 Jun; 160(12):1842-7. PubMed ID: 10871979 [TBL] [Abstract][Full Text] [Related]
33. Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension. Schnaper HW Angiology; 1989 Apr; 40(4 Pt 2):389-95. PubMed ID: 2650582 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of quinapril in the elderly hypertensive patient. Forette B; Koen R; Vicaut E Am Heart J; 1992 May; 123(5):1426-32. PubMed ID: 1575170 [TBL] [Abstract][Full Text] [Related]
35. A comparison of the efficacy and safety of quinapril with that of enalapril in the treatment of mild to moderate essential hypertension. Taylor SH Angiology; 1989 Apr; 40(4 Pt 2):382-8. PubMed ID: 2539763 [TBL] [Abstract][Full Text] [Related]
36. The role of tissue renin-angiotensin systems in hypertension and effects of chronic converting-enzyme inhibition. Keuneke C; Yacullo R; Metzger R; Hellmann T; Peters J; Ganten D Eur Heart J; 1990 May; 11 Suppl D():11-6. PubMed ID: 2163328 [TBL] [Abstract][Full Text] [Related]
37. Improved survival in rats administered NG-nitro L-arginine methyl ester due to converting enzyme inhibition. Michel JB; Xu Y; Blot S; Philippe M; Chatellier G J Cardiovasc Pharmacol; 1996 Jul; 28(1):142-8. PubMed ID: 8797148 [TBL] [Abstract][Full Text] [Related]
38. Angiotensin-converting enzyme inhibition with quinapril (CI-906) and captopril in spontaneously hypertensive rats with suppressed renin-angiotensin system. Säynävälammi P; Pörsti I Methods Find Exp Clin Pharmacol; 1987 Jun; 9(6):325-31. PubMed ID: 3309510 [TBL] [Abstract][Full Text] [Related]
39. Effect of timing of administration on the plasma ACE inhibitory activity and the antihypertensive effect of quinapril. Palatini P; Racioppa A; Raule G; Zaninotto M; Penzo M; Pessina AC Clin Pharmacol Ther; 1992 Oct; 52(4):378-83. PubMed ID: 1330398 [TBL] [Abstract][Full Text] [Related]
40. Effects of quinapril hydrochloride in patients with essential hypertension and impaired renal function. Owada A; Nonoguchi H; Terada Y; Marumo F; Tomita K Clin Exp Hypertens; 1997 May; 19(4):495-502. PubMed ID: 9140710 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]